This inventor holds 1 USPTO granted patent. Top assignee: Universitè Laval. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013
Title: The Innovations of Daniel Beaulieu
Introduction
Daniel Beaulieu is a notable inventor based in Canada, recognized for his contributions to medical science. He has made significant strides in the field of myotonic dystrophy, particularly through his innovative research and patent.
Latest Patents
Daniel Beaulieu holds a patent for "Prostaglandin E2 modulation and uses thereof." This patent describes methods, uses, kits, and products for the prognosis, diagnosis, prevention, and treatment of myotonic dystrophy type 1 (DM1). More specifically, it focuses on the congenital form of myotonic dystrophy type 1 (cDM1), utilizing changes in or modulation of prostaglandin E (PGE).
Career Highlights
Beaulieu is affiliated with Université Laval, where he has been instrumental in advancing research related to his patent. His work has the potential to significantly impact the lives of individuals affected by myotonic dystrophy.
Collaborations
Daniel Beaulieu has collaborated with esteemed colleagues, including Jack Puymirat and Pierre Chapdelaine, to further his research and innovations in the field.
Conclusion
Daniel Beaulieu's work exemplifies the spirit of innovation in medical research, particularly in addressing myotonic dystrophy. His contributions through his patent and collaborations highlight the importance of scientific advancement in improving health outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile